Havana, Mar 9 (Prensa Latina) The clinical trial developed by the Finlay Institute for the heptavalent vaccine against pneumococci will be extended to other municipalities in Havana, said doctor Meybis Rodriguez, Promoter Coordinator of the research.
Rodriguez told the Prensa Latina news agency that currently the vaccination process takes place in the municipality of La Lisa and Marianao, west of Havana, and the central province of Cienfuegos, where the research started in 2014, and this time, the municipality Plaza de la Revolucion will be included.
The children will be selected from the health areas of the Moncada and 19 de Abril polyclinics in Havana.
Rodriguez said that during March the research teams will be prepared and the vaccination stage at the Borras-Marfan pediatric hospital is scheduled for April.
‘So far we have not had adverse effects related to the vaccine, so we will continue to extend the trial to other provinces in the country. In the second stage of the research, the eastern province of Camaguey will be included,’ she said.
Once these researches are concluded, the vaccine will be included in the vaccination network established by the public health system of Cuba, which includes immunization against 13 diseases.
The heptavalent pediatric vaccine will be registered under the trademark Quimi-Vio and will reach all Cuban provinces.